Novel RAS inhibitors, such as RMC-7977, repressing the phosphorylation of downstream effectors of the MAPK pathway are potent against FLT3-ITD- and RAS-mutated AML cell lines [133] and are being highlighted as promising partners for VEN. Here, FLT3 is linked to acute myeloid leukemia.